Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial

NCT06662877 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06662877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06662877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
November 25, 2024
Completion date
September 1, 2029
Enrollment
206 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, chemotherapy, second line treatment, tyrosine kinase inhibitor